3-iodobenzylguanidine has been researched along with Anterior Wall Myocardial Infarction in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, Y; Bom, HS; Cho, JG; Cho, JY; Chong, A; Hong, YJ; Jang, SY; Jeong, HC; Jeong, IS; Jeong, MH; Kang, JC; Kim, HK; Kim, J; Kim, JH; Kim, JM; Kim, KH; Kim, MS; Kim, SS; Lee, KH; Lim, KS; Oh, SG; Park, DS; Park, HW; Park, JC; Park, KH; Ryu, SH; Sim, DS; Song, HC; Yoon, HJ; Yoon, NS | 1 |
1 other study(ies) available for 3-iodobenzylguanidine and Anterior Wall Myocardial Infarction
| Article | Year |
|---|---|
Cardioprotective effect of fimasartan, a new angiotensin receptor blocker, in a porcine model of acute myocardial infarction.
Topics: 3-Iodobenzylguanidine; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anterior Wall Myocardial Infarction; Biphenyl Compounds; Cardiotonic Agents; Disease Models, Animal; Echocardiography; Fluorodeoxyglucose F18; Perindopril; Positron-Emission Tomography; Pyrimidines; Random Allocation; Swine; Tetrazoles; Tomography, Emission-Computed, Single-Photon; Valsartan; Ventricular Function, Left | 2015 |